title: [Treatment of tuberculosis in France].
abstract: In France, the treatment of tuberculosis must take into account both the low rate of multiresistance and the relatively low cost of drugs (the cost of 6 months treatment is about equivalent to the cost of 1 day of hospitalization). A six-month regimen has been recommended in France since 1981. Streptomycin is no longer used routinely. A combination of rifampicin, isoniazid and pyrazinamide is the basis of initial treatment either in as a single medication (Rifater) or taken separately. Ethambutol is added at treatment onset, especially when there was a doubt about resistance. The second phase uses isoniazid and rifampicin, together (Rifanah) or separate.
authors.affiliation: Service de pneumologie, Groupe hospitalier Pitié-Salpêtrière, Paris.
authors.forename: B
authors.initials: B
authors.lastname: Dautzenberg
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D016867:Immunocompromised Host; D017093:Liver Failure / Q000628:therapy; D008297:Male; D011247:Pregnancy; D051437:Renal Insufficiency / Q000628:therapy; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents
vernacular_title: Traitement de la tuberculose en France.